|
1
|
French SW, Lee J, Zhong J, Morgan TR,
Buslon V, Lungo W and French BA: Alcoholic liver disease -
Hepatocellular carcinoma transformation. J Gastrointest Oncol.
3:174–181. 2012.PubMed/NCBI
|
|
2
|
Mann CD, Neal CP, Garcea G, Manson MM,
Dennison AR and Berry DP: Prognostic molecular markers in
hepatocellular carcinoma: A systematic review. Eur J Cancer.
43:979–992. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Apte SS, Mattei MG and Olsen BR: Cloning
of the cDNA encoding human tissue inhibitor of metalloproteinases-3
(TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Genomics.
19:86–90. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu WH, Yu S, Meng Q, Brew K and Woessner
JF Jr: TIMP-3 binds to sulfated glycosaminoglycans of the
extracellular matrix. J Biol Chem. 275:31226–31232. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anand-Apte B, Bao L, Smith R, Iwata K,
Olsen BR, Zetter B and Apte SS: A review of tissue inhibitor of
metalloproteinases-3 (TIMP-3) and experimental analysis of its
effect on primary tumor growth. Biochem Cell Biol. 74:853–862.
1996. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kallio JP, Hopkins-Donaldson S, Baker AH
and Kähäri VM: TIMP-3 promotes apoptosis in nonadherent small cell
lung carcinoma cells lacking functional death receptor pathway. Int
J Cancer. 128:991–996. 2011. View Article : Google Scholar
|
|
7
|
Bachman KE, Herman JG, Corn PG, Merlo A,
Costello JF, Cavenee WK, Baylin SB and Graff JR:
Methylation-associated silencing of the tissue inhibitor of
metalloproteinase-3 gene suggest a suppressor role in kidney,
brain, and other human cancers. Cancer Res. 59:798–802.
1999.PubMed/NCBI
|
|
8
|
Shen B, Chu ES, Zhao G, Man K, Wu CW,
Cheng JT, Li G, Nie Y, Lo CM, Teoh N, et al: PPARgamma inhibits
hepatocellular carcinoma metastases in vitro and in mice. Br J
Cancer. 106:1486–1494. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Almog N, Ma L, Schwager C, Brinkmann BG,
Beheshti A, Vajkoczy P, Folkman J, Hlatky L and Abdollahi A:
Consensus microRNAs governing the switch of dormant tumors to the
fast-growing angiogenic phenotype. PLoS One. 7:e440012012.
View Article : Google Scholar
|
|
10
|
Nagao Y, Hisaoka M, Matsuyama A, Kanemitsu
S, Hamada T, Fukuyama T, Nakano R, Uchiyama A, Kawamoto M,
Yamaguchi K, et al: Association of microRNA-21 expression with its
targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma. Mod
Pathol. 25:112–121. 2012. View Article : Google Scholar
|
|
11
|
Yu D, Zhou H, Xun Q, Xu X, Ling J and Hu
Y: microRNA-103 regulates the growth and invasion of endometrial
cancer cells through the downregulation of tissue inhibitor of
metalloproteinase 3. Oncol Lett. 3:1221–1226. 2012.PubMed/NCBI
|
|
12
|
Guo JX, Tao QS, Lou PR, Chen XC, Chen J
and Yuan GB: miR-181b as a potential molecular target for
anticancer therapy of gastric neoplasms. Asian Pac J Cancer Prev.
13:2263–2267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Panda H, Chuang TD, Luo X and Chegini N:
Endometrial miR-181a and miR-98 expression is altered during
transition from normal into cancerous state and target PGR, PGRMC1,
CYP19A1, DDX3X, and TIMP3. J Clin Endocrinol Metab. 97:E1316–E1326.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang C, Zhang J, Hao J, Shi Z, Wang Y,
Han L, Yu S, You Y, Jiang T, Wang J, et al: High level of
miR-221/222 confers increased cell invasion and poor prognosis in
glioma. J Transl Med. 10:1192012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lü GL, Wen JM, Xu JM, Zhang M, Xu RB and
Tian BL: Relationship between TIMP-3 expression and promoter
methylation of TIMP-3 gene in hepatocellular carcinoma. Zhonghua
Bing. Li Xue Za Zhi. 32:230–233. 2003.In Chinese.
|
|
16
|
Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ and
Kang GH: Aberrant CpG island hypermethylation along multistep
hepatocarcinogenesis. Am J Pathol. 163:1371–1378. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bond M, Murphy G, Bennett MR, Newby AC and
Baker AH: Tissue inhibitor of metalloproteinase-3 induces a
Fas-associated death domain-dependent type II apoptotic pathway. J
Biol Chem. 277:13787–13795. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Masson D, Rioux-Leclercq N, Fergelot P,
Jouan F, Mottier S, Théoleyre S, Bach-Ngohou K, Patard JJ and Denis
MG: Loss of expression of TIMP3 in clear cell renal cell carcinoma.
Eur J Cancer. 46:1430–1437. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hoque MO, Begum S, Brait M, Jeronimo C,
Zahurak M, Ostrow KL, Rosenbaum E, Trock B, Westra WH, Schoenberg
M, et al: Tissue inhibitor of metalloproteinases-3 promoter
methylation is an independent prognostic factor for bladder cancer.
J Urol. 179:743–747. 2008. View Article : Google Scholar
|
|
20
|
Gu P, Xing X, Tänzer M, Röcken C, Weichert
W, Ivanauskas A, Pross M, Peitz U, Malfertheiner P, Schmid RM, et
al: Frequent loss of TIMP-3 expression in progression of esophageal
and gastric adenocarcinomas. Neoplasia. 10:563–572. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stetler-Stevenson WG: The role of matrix
metalloproteinases in tumor invasion, metastasis, and angiogenesis.
Surg Oncol Clin N Am. 10:383–392. x2001.PubMed/NCBI
|
|
22
|
Amălinei C, Căruntu ID, Giuşcă SE and
Bălan RA: Matrix metalloproteinases involvement in pathologic
conditions. Rom J Morphol Embryol. 51:215–228. 2010.
|
|
23
|
Jiao Y, Feng X, Zhan Y, Wang R, Zheng S,
Liu W and Zeng X: Matrix metalloproteinase-2 promotes αvβ3
integrin-mediated adhesion and migration of human melanoma cells by
cleaving fibronectin. PLoS One. 7:e415912012. View Article : Google Scholar
|
|
24
|
Chetty C, Vanamala SK, Gondi CS, Dinh DH,
Gujrati M and Rao JS: MMP-9 induces CD44 cleavage and CD44 mediated
cell migration in glioblastoma xenograft cells. Cell Signal.
24:549–559. 2012. View Article : Google Scholar :
|
|
25
|
Yu Q and Stamenkovic I: Cell
surface-localized matrix metalloproteinase-9 proteolytically
activates TGF-beta and promotes tumor invasion and angiogenesis.
Genes Dev. 14:163–176. 2000.PubMed/NCBI
|
|
26
|
Yu BF, Wu J, Zhang Y, Sung HW, Xie J and
Li RK: Ultrasound-targeted HSVtk and Timp3 gene delivery for
synergistically enhanced antitumor effects in hepatoma. Cancer Gene
Ther. 20:290–297. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hama R, Watanabe Y, Shinada K, Yamada Y,
Ogata Y, Yoshida Y, Tamura T, Hiraishi T, Oikawa R, Sakurai J, et
al: Characterization of DNA hypermethylation in two cases of
peritoneal mesothelioma. Tumour Biol. 33:2031–2040. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang H, Wang YS, Han G and Shi Y: TIMP-3
gene transfection suppresses invasive and metastatic capacity of
human hepatocarcinoma cell line HCC-7721. Hepatobiliary Pancreat
Dis Int. 6:487–491. 2007.PubMed/NCBI
|
|
29
|
Tian H, Huang ML, Liu KY, Jia ZB, Sun L,
Jiang SL, Liu W, McDonald Kinkaid HY, Wu J and Li RK: Inhibiting
matrix metalloproteinase by cell-based timp-3 gene transfer
effectively treats acute and chronic ischemic cardiomyopathy. Cell
Transplant. 21:1039–1053. 2012. View Article : Google Scholar
|
|
30
|
Wu DW, Tsai LH, Chen PM, Lee MC, Wang L,
Chen CY, Cheng YW and Lee H: Loss of TIMP-3 promotes tumor invasion
via elevated IL-6 production and predicts poor survival and relapse
in HPV-infected non-small cell lung cancer. Am J Pathol.
181:1796–1806. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ju HX, An B, Okamoto Y, Shinjo K,
Kanemitsu Y, Komori K, Hirai T, Shimizu Y, Sano T, Sawaki A, et al:
Distinct profiles of epigenetic evolution between colorectal
cancers with and without metastasis. Am J Pathol. 178:1835–1846.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lacy ER, Filippov I, Lewis WS, Otieno S,
Xiao L, Weiss S, Hengst L and Kriwacki RW: p27 binds cyclin-CDK
complexes through a sequential mechanism involving binding-induced
protein folding. Nat Struct Mol Biol. 11:358–364. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guo J, Ma Q, Zhou X, Fan P, Shan T and
Miao D: Inactivation of p27kip1 promotes chemical
hepatocarcinogenesis through enhancing inflammatory cytokine
secretion and STAT3 signaling activation. J Cell Physiol.
228:1967–1976. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ding WX, Ni HM, DiFrancesca D, Stolz DB
and Yin XM: Bid-dependent generation of oxygen radicals promotes
death receptor activation-induced apoptosis in murine hepatocytes.
Hepatology. 40:403–413. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hsu CH, Peng KL, Kang ML, Chen YR, Yang
YC, Tsai CH, Chu CS, Jeng YM, Chen YT, Lin FM, et al: TET1
suppresses cancer invasion by activating the tissue inhibitors of
metalloproteinases. Cell Rep. 2:568–579. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang J, Ding W, Sun B, Jing R, Huang H,
Shi G and Wang H: Targeting of colorectal cancer growth,
metastasis, and anti-apoptosis in BALB/c nude mice via APRIL siRNA.
Mol Cell Biochem. 363:1–10. 2012. View Article : Google Scholar
|
|
37
|
Bunz F, Dutriaux A, Lengauer C, Waldman T,
Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B:
Requirement for p53 and p21 to sustain G arrest after DNA damage.
Science. 282:1497–1501. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Smits VA, Klompmaker R, Arnaud L, Rijksen
G, Nigg EA and Medema RH: Polo-like kinase-1 is a target of the DNA
damage checkpoint. Nat Cell Biol. 2:672–676. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schwartz GK and Shah MA: Targeting the
cell cycle: A new approach to cancer therapy. J Clin Oncol.
23:9408–9421. 2005. View Article : Google Scholar : PubMed/NCBI
|
